BindingDB logo
myBDB logout

USPatent US9637493

Compile data set for download or QSAR
Found 47 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)		LigandTarget/Host
Links		Ligand
Links		Trg + Lig
Links		Ki
nM		ΔG°
kJ/mole		IC50
nM		Kd
nM		EC50/IC50
nM		koff
s-1		kon
M-1s-1		pHTemp
°C
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326330
PNG
(4-(5-chloropyridin-3-yl)-6- [(1R or S)-1-fluoro-1-...)
Show SMILES C[C@H]1CC[C@H](Cn2c(cc3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)C(C)(F)c2ncccc2F)CC1 |r,wU:4.4,wD:1.0,(5.97,-4.79,;4.64,-4.02,;4.64,-2.48,;3.3,-1.71,;1.97,-2.48,;.64,-1.71,;.64,-.17,;1.54,1.08,;.64,2.33,;-.83,1.85,;-2.16,2.62,;-3.49,1.85,;-3.49,.31,;-2.16,-.46,;-2.16,-2,;-.83,-2.77,;-.83,-4.31,;-2.16,-5.08,;-3.49,-4.31,;-4.83,-5.08,;-3.49,-2.77,;-.83,.31,;-4.83,2.62,;-6.16,1.85,;-4.83,4.16,;3.08,1.08,;4.42,.31,;3.08,-.46,;3.85,2.41,;5.39,2.41,;6.16,3.75,;5.39,5.08,;3.85,5.08,;3.08,3.75,;1.54,3.75,;1.97,-4.02,;3.3,-4.79,)|
Show InChI InChI=1S/C27H26ClF2N5O2/c1-15-5-7-16(8-6-15)14-35-21(27(2,30)24-19(29)4-3-9-32-24)11-20-23(35)22(34-25(33-20)26(36)37)17-10-18(28)13-31-12-17/h3-4,9-13,15-16H,5-8,14H2,1-2H3,(H,36,37)/t15-,16-,27?
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326332
PNG
(3-{4-(5-chloropyridin-3- yl)-6-[(1R or S)-1-fluoro...)
Show SMILES C[C@H]1CC[C@H](Cn2c(cc3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)C(C)(F)c2ncccc2F)CC1 |r,wU:4.4,wD:1.0,(6.49,-5.23,;5.16,-4.46,;5.16,-2.92,;3.82,-2.15,;2.49,-2.92,;1.16,-2.15,;1.16,-.61,;2.06,.64,;1.16,1.88,;-.31,1.41,;-1.64,2.18,;-2.98,1.41,;-2.98,-.13,;-1.64,-.9,;-1.64,-2.44,;-.31,-3.21,;-.31,-4.75,;-1.64,-5.52,;-2.98,-4.75,;-4.31,-5.52,;-2.98,-3.21,;-.31,-.13,;-4.31,2.18,;-5.78,1.7,;-6.68,2.95,;-5.78,4.19,;-6.55,5.52,;-4.31,3.72,;3.6,.64,;4.93,-.13,;3.6,-.9,;4.37,1.97,;5.91,1.97,;6.68,3.3,;5.91,4.64,;4.37,4.64,;3.6,3.3,;2.06,3.3,;2.49,-4.46,;3.82,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326329
PNG
(3-{4-(5-chloropyridin-3- yl)-6-[fluoro(2- fluoroph...)
Show SMILES C[C@H]1CC[C@H](Cn2c(cc3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)C(F)c2ccccc2F)CC1 |r,wU:4.4,wD:1.0,(6.36,-5.23,;5.02,-4.46,;5.02,-2.92,;3.69,-2.15,;2.36,-2.92,;1.02,-2.15,;1.02,-.61,;1.93,.64,;1.02,1.88,;-.44,1.41,;-1.78,2.18,;-3.11,1.41,;-3.11,-.13,;-1.78,-.9,;-1.78,-2.44,;-.44,-3.21,;-.44,-4.75,;-1.78,-5.52,;-3.11,-4.75,;-4.44,-5.52,;-3.11,-3.21,;-.44,-.13,;-4.44,2.18,;-5.91,1.7,;-6.81,2.95,;-5.91,4.19,;-6.68,5.52,;-4.44,3.72,;3.47,.64,;4.24,-.7,;4.24,1.97,;3.84,3.46,;4.93,4.55,;6.41,4.15,;6.81,2.66,;5.72,1.57,;6.12,.08,;2.36,-4.46,;3.69,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326328
PNG
(4-(5-chloropyridin-3-yl)-6- [fluoro(2- fluoropheny...)
Show SMILES C[C@H]1CC[C@H](Cn2c(cc3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)C(F)c2ccccc2F)CC1 |r,wU:4.4,wD:1.0,(5.97,-4.79,;4.64,-4.02,;4.64,-2.48,;3.3,-1.71,;1.97,-2.48,;.64,-1.71,;.64,-.17,;1.54,1.08,;.64,2.33,;-.83,1.85,;-2.16,2.62,;-3.49,1.85,;-3.49,.31,;-2.16,-.46,;-2.16,-2,;-.83,-2.77,;-.83,-4.31,;-2.16,-5.08,;-3.49,-4.31,;-4.83,-5.08,;-3.49,-2.77,;-.83,.31,;-4.83,2.62,;-6.16,1.85,;-4.83,4.16,;3.08,1.08,;3.85,-.25,;3.85,2.41,;3.08,3.75,;3.85,5.08,;5.39,5.08,;6.16,3.75,;5.39,2.41,;6.16,1.08,;1.97,-4.02,;3.3,-4.79,)|
Show InChI InChI=1S/C27H25ClF2N4O2/c1-15-6-8-16(9-7-15)14-34-22(23(30)19-4-2-3-5-20(19)29)11-21-25(34)24(33-26(32-21)27(35)36)17-10-18(28)13-31-12-17/h2-5,10-13,15-16,23H,6-9,14H2,1H3,(H,35,36)/t15-,16-,23?
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326332
PNG
(3-{4-(5-chloropyridin-3- yl)-6-[(1R or S)-1-fluoro...)
Show SMILES C[C@H]1CC[C@H](Cn2c(cc3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)C(C)(F)c2ncccc2F)CC1 |r,wU:4.4,wD:1.0,(6.49,-5.23,;5.16,-4.46,;5.16,-2.92,;3.82,-2.15,;2.49,-2.92,;1.16,-2.15,;1.16,-.61,;2.06,.64,;1.16,1.88,;-.31,1.41,;-1.64,2.18,;-2.98,1.41,;-2.98,-.13,;-1.64,-.9,;-1.64,-2.44,;-.31,-3.21,;-.31,-4.75,;-1.64,-5.52,;-2.98,-4.75,;-4.31,-5.52,;-2.98,-3.21,;-.31,-.13,;-4.31,2.18,;-5.78,1.7,;-6.68,2.95,;-5.78,4.19,;-6.55,5.52,;-4.31,3.72,;3.6,.64,;4.93,-.13,;3.6,-.9,;4.37,1.97,;5.91,1.97,;6.68,3.3,;5.91,4.64,;4.37,4.64,;3.6,3.3,;2.06,3.3,;2.49,-4.46,;3.82,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 4.5n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326330
PNG
(4-(5-chloropyridin-3-yl)-6- [(1R or S)-1-fluoro-1-...)
Show SMILES C[C@H]1CC[C@H](Cn2c(cc3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)C(C)(F)c2ncccc2F)CC1 |r,wU:4.4,wD:1.0,(5.97,-4.79,;4.64,-4.02,;4.64,-2.48,;3.3,-1.71,;1.97,-2.48,;.64,-1.71,;.64,-.17,;1.54,1.08,;.64,2.33,;-.83,1.85,;-2.16,2.62,;-3.49,1.85,;-3.49,.31,;-2.16,-.46,;-2.16,-2,;-.83,-2.77,;-.83,-4.31,;-2.16,-5.08,;-3.49,-4.31,;-4.83,-5.08,;-3.49,-2.77,;-.83,.31,;-4.83,2.62,;-6.16,1.85,;-4.83,4.16,;3.08,1.08,;4.42,.31,;3.08,-.46,;3.85,2.41,;5.39,2.41,;6.16,3.75,;5.39,5.08,;3.85,5.08,;3.08,3.75,;1.54,3.75,;1.97,-4.02,;3.3,-4.79,)|
Show InChI InChI=1S/C27H26ClF2N5O2/c1-15-5-7-16(8-6-15)14-35-21(27(2,30)24-19(29)4-3-9-32-24)11-20-23(35)22(34-25(33-20)26(36)37)17-10-18(28)13-31-12-17/h3-4,9-13,15-16H,5-8,14H2,1-2H3,(H,36,37)/t15-,16-,27?
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326298
PNG
(5-[2-amino-4- (trifluoromethyl) benzyl]-4-{[(1R)-1...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(cc3N)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H28F3N5O2/c1-15-5-3-8-18(11-15)23-13-22-24(36(23)14-19-9-10-20(12-21(19)32)28(29,30)31)25(35-26(34-22)27(37)38)33-16(2)17-6-4-7-17/h3,5,8-13,16-17H,4,6-7,14,32H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326326
PNG
(3-[4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(CCc3cccnc3)c3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1 |r,wU:4.4,wD:1.0,(6.48,-5.23,;5.14,-4.46,;5.14,-2.92,;3.81,-2.15,;2.48,-2.92,;1.14,-2.15,;1.14,-.61,;2.05,.64,;1.14,1.88,;1.54,3.37,;3.03,3.77,;4.12,2.68,;3.72,1.19,;4.81,.1,;6.29,.5,;6.69,1.99,;5.6,3.08,;-.32,1.41,;-1.66,2.18,;-2.99,1.41,;-2.99,-.13,;-1.66,-.9,;-1.66,-2.44,;-.32,-3.21,;-.32,-4.75,;-1.66,-5.52,;-2.99,-4.75,;-4.32,-5.52,;-2.99,-3.21,;-.32,-.13,;-4.32,2.18,;-5.79,1.7,;-6.69,2.95,;-5.79,4.19,;-6.56,5.52,;-4.32,3.72,;2.48,-4.46,;3.81,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326309
PNG
(5-(4-bromo-3- fluorobenzyl)-4-{[(1R)- 1- cyclobuty...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(Br)c(F)c3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C27H26BrFN4O2/c1-15-5-3-8-19(11-15)23-13-22-24(33(23)14-17-9-10-20(28)21(29)12-17)25(32-26(31-22)27(34)35)30-16(2)18-6-4-7-18/h3,5,8-13,16,18H,4,6-7,14H2,1-2H3,(H,34,35)(H,30,31,32)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326295
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 6-(4-methylpyr...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cc(C)ccn3)n(Cc3ccc(cc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C27H26F3N5O2/c1-15-10-11-31-20(12-15)22-13-21-23(35(22)14-17-6-8-19(9-7-17)27(28,29)30)24(34-25(33-21)26(36)37)32-16(2)18-4-3-5-18/h6-13,16,18H,3-5,14H2,1-2H3,(H,36,37)(H,32,33,34)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 18n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326306
PNG
(5-(4-chloro-3- fluorobenzyl)-4-{[(1R)- 1- cyclobut...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(Cl)c(F)c3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C27H26ClFN4O2/c1-15-5-3-8-19(11-15)23-13-22-24(33(23)14-17-9-10-20(28)21(29)12-17)25(32-26(31-22)27(34)35)30-16(2)18-6-4-7-18/h3,5,8-13,16,18H,4,6-7,14H2,1-2H3,(H,34,35)(H,30,31,32)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 21n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326296
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 6-[4-(1- methy...)
Show SMILES CC(C)c1ccnc(c1)-c1cc2nc(nc(N[C@H](C)C3CCC3)c2n1Cc1ccc(cc1)C(F)(F)F)C(O)=O |r|
Show InChI InChI=1S/C29H30F3N5O2/c1-16(2)20-11-12-33-22(13-20)24-14-23-25(37(24)15-18-7-9-21(10-8-18)29(30,31)32)26(36-27(35-23)28(38)39)34-17(3)19-5-4-6-19/h7-14,16-17,19H,4-6,15H2,1-3H3,(H,38,39)(H,34,35,36)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 26n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326324
PNG
(3-[4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Show SMILES CC(C)Cc1cn(C[C@H]2CC[C@H](C)CC2)c2c(nc(nc12)-c1noc(=O)[nH]1)-c1cncc(Cl)c1 |r,wU:8.7,wD:11.11,(3.54,5.25,;3.14,3.77,;4.23,2.68,;1.65,3.37,;1.25,1.88,;2.16,.64,;1.25,-.61,;1.25,-2.15,;2.58,-2.92,;3.92,-2.15,;5.25,-2.92,;5.25,-4.46,;6.59,-5.23,;3.92,-5.23,;2.58,-4.46,;-.21,-.13,;-1.55,-.9,;-2.88,-.13,;-2.88,1.41,;-1.55,2.18,;-.21,1.41,;-4.22,2.18,;-5.68,1.7,;-6.59,2.95,;-5.68,4.19,;-6.45,5.52,;-4.22,3.72,;-1.55,-2.44,;-.21,-3.21,;-.21,-4.75,;-1.55,-5.52,;-2.88,-4.75,;-4.22,-5.52,;-2.88,-3.21,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 35n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326320
PNG
(3-{4-(5-chloropyridin-3- yl)-7-methyl-5-[(trans-4-...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(C)c3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.23,;5.25,-4.46,;5.25,-2.92,;3.92,-2.15,;2.58,-2.92,;1.25,-2.15,;1.25,-.61,;2.16,.64,;1.25,1.88,;2.02,3.21,;-.21,1.41,;-1.55,2.18,;-2.88,1.41,;-2.88,-.13,;-1.55,-.9,;-1.55,-2.44,;-.21,-3.21,;-.21,-4.75,;-1.55,-5.52,;-2.88,-4.75,;-4.22,-5.52,;-2.88,-3.21,;-.21,-.13,;-4.22,2.18,;-5.68,1.7,;-6.59,2.95,;-5.68,4.19,;-6.45,5.52,;-4.22,3.72,;2.58,-4.46,;3.92,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 36n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326291
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 6-(2-methoxy-5...)
Show SMILES COc1ccc(C)cc1-c1cc2nc(nc(N[C@H](C)C3CCC3)c2n1Cc1ccc(cc1)C(F)(F)F)C(O)=O |r|
Show InChI InChI=1S/C29H29F3N4O3/c1-16-7-12-24(39-3)21(13-16)23-14-22-25(36(23)15-18-8-10-20(11-9-18)29(30,31)32)26(35-27(34-22)28(37)38)33-17(2)19-5-4-6-19/h7-14,17,19H,4-6,15H2,1-3H3,(H,37,38)(H,33,34,35)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 42n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326325
PNG
(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(CCc3cccnc3)c3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)CC1 |r,wU:4.4,wD:1.0,(5.96,-4.35,;4.63,-3.58,;4.63,-2.04,;3.29,-1.27,;1.96,-2.04,;.62,-1.27,;.62,.27,;1.53,1.51,;.62,2.76,;1.02,4.25,;2.51,4.65,;3.6,3.56,;3.2,2.07,;4.29,.98,;5.78,1.38,;6.18,2.87,;5.09,3.96,;-.84,2.28,;-2.17,3.05,;-3.51,2.28,;-3.51,.74,;-2.17,-.03,;-2.17,-1.57,;-.84,-2.34,;-.84,-3.88,;-2.17,-4.65,;-3.51,-3.88,;-4.84,-4.65,;-3.51,-2.34,;-.84,.74,;-4.84,3.05,;-6.18,2.28,;-4.84,4.59,;1.96,-3.58,;3.29,-4.35,)|
Show InChI InChI=1S/C27H28ClN5O2/c1-17-4-6-19(7-5-17)15-33-16-20(9-8-18-3-2-10-29-12-18)23-25(33)24(32-26(31-23)27(34)35)21-11-22(28)14-30-13-21/h2-3,10-14,16-17,19H,4-9,15H2,1H3,(H,34,35)/t17-,19-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 47n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326297
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 7-methyl-6-[4-...)
Show SMILES CC(C)c1ccnc(c1)-c1c(C)c2nc(nc(N[C@H](C)C3CCC3)c2n1Cc1ccc(cc1)C(F)(F)F)C(O)=O |r|
Show InChI InChI=1S/C30H32F3N5O2/c1-16(2)21-12-13-34-23(14-21)25-17(3)24-26(38(25)15-19-8-10-22(11-9-19)30(31,32)33)27(37-28(36-24)29(39)40)35-18(4)20-6-5-7-20/h8-14,16,18,20H,5-7,15H2,1-4H3,(H,39,40)(H,35,36,37)/t18-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 50n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326327
PNG
(3-[4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(Cc3cccnc3)c3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.29,;5.25,-4.52,;5.25,-2.98,;3.92,-2.21,;2.58,-2.98,;1.25,-2.21,;1.25,-.67,;2.16,.57,;1.25,1.82,;1.65,3.3,;3.14,3.7,;3.54,5.19,;5.02,5.59,;6.11,4.5,;5.71,3.01,;4.23,2.61,;-.21,1.34,;-1.55,2.11,;-2.88,1.34,;-2.88,-.2,;-1.55,-.97,;-1.55,-2.51,;-.21,-3.28,;-.21,-4.82,;-1.55,-5.59,;-2.88,-4.82,;-4.22,-5.59,;-2.88,-3.28,;-.21,-.2,;-4.22,2.11,;-5.68,1.64,;-6.59,2.88,;-5.68,4.13,;-6.45,5.46,;-4.22,3.65,;2.58,-4.52,;3.92,-5.29,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 52n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326322
PNG
(5-{7-benzyl-4-(5- chloropyridin-3-yl)-5- [(trans-4...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(Cc3ccccc3)c3nc(nc(-c4cncc(Cl)c4)c23)-c2n[nH]c(=O)o2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.29,;5.25,-4.52,;5.25,-2.98,;3.92,-2.21,;2.58,-2.98,;1.25,-2.21,;1.25,-.67,;2.16,.57,;1.25,1.82,;1.65,3.3,;3.14,3.7,;4.23,2.61,;5.71,3.01,;6.11,4.5,;5.02,5.59,;3.54,5.19,;-.21,1.34,;-1.55,2.11,;-2.88,1.34,;-2.88,-.2,;-1.55,-.97,;-1.55,-2.51,;-.21,-3.28,;-.21,-4.82,;-1.55,-5.59,;-2.88,-4.82,;-4.22,-5.59,;-2.88,-3.28,;-.21,-.2,;-4.22,2.11,;-5.68,1.64,;-6.59,2.88,;-5.68,4.13,;-6.45,5.46,;-4.22,3.65,;2.58,-4.52,;3.92,-5.29,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 54n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326315
PNG
(3-{4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Show SMILES C[C@H]1CC[C@H](Cn2ccc3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.23,;5.25,-4.46,;5.25,-2.92,;3.92,-2.15,;2.58,-2.92,;1.25,-2.15,;1.25,-.61,;2.16,.64,;1.25,1.88,;-.21,1.41,;-1.55,2.18,;-2.88,1.41,;-2.88,-.13,;-1.55,-.9,;-1.55,-2.44,;-.21,-3.21,;-.21,-4.75,;-1.55,-5.52,;-2.88,-4.75,;-4.22,-5.52,;-2.88,-3.21,;-.21,-.13,;-4.22,2.18,;-5.68,1.7,;-6.59,2.95,;-5.68,4.19,;-6.45,5.52,;-4.22,3.72,;2.58,-4.46,;3.92,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 57n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326287
PNG
((R)-4-((1- cyclobutylethyl)amino)- 6-(2-fluoro-5- ...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cc(C)ccc3F)n(Cc3ccc(cc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H26F4N4O2/c1-15-6-11-21(29)20(12-15)23-13-22-24(36(23)14-17-7-9-19(10-8-17)28(30,31)32)25(35-26(34-22)27(37)38)33-16(2)18-4-3-5-18/h6-13,16,18H,3-5,14H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 62n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326293
PNG
(6-(2-chloro-5- methylphenyl)-4-{[(1R)- 1- cyclobut...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cc(C)ccc3Cl)n(Cc3ccc(cc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H26ClF3N4O2/c1-15-6-11-21(29)20(12-15)23-13-22-24(36(23)14-17-7-9-19(10-8-17)28(30,31)32)25(35-26(34-22)27(37)38)33-16(2)18-4-3-5-18/h6-13,16,18H,3-5,14H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 63n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326323
PNG
(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Show SMILES CC(C)Cc1cn(C[C@H]2CC[C@H](C)CC2)c2c(nc(nc12)C(O)=O)-c1cncc(Cl)c1 |r,wU:8.7,wD:11.11,(3.02,5.39,;2.62,3.9,;3.71,2.81,;1.13,3.5,;.73,2.02,;1.64,.77,;.73,-.48,;.73,-2.02,;2.07,-2.79,;3.4,-2.02,;4.73,-2.79,;4.73,-4.33,;6.07,-5.1,;3.4,-5.1,;2.07,-4.33,;-.73,0,;-2.07,-.77,;-3.4,0,;-3.4,1.54,;-2.07,2.31,;-.73,1.54,;-4.73,2.31,;-6.07,1.54,;-4.73,3.85,;-2.07,-2.31,;-.73,-3.08,;-.73,-4.62,;-2.07,-5.39,;-3.4,-4.62,;-4.73,-5.39,;-3.4,-3.08,)|
Show InChI InChI=1S/C24H29ClN4O2/c1-14(2)8-18-13-29(12-16-6-4-15(3)5-7-16)22-20(17-9-19(25)11-26-10-17)27-23(24(30)31)28-21(18)22/h9-11,13-16H,4-8,12H2,1-3H3,(H,30,31)/t15-,16-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 71n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326321
PNG
(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(-c3ccccc3)c3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)CC1 |r,wU:4.4,wD:1.0,(6.07,-5.64,;4.73,-4.87,;4.73,-3.33,;3.4,-2.56,;2.07,-3.33,;.73,-2.56,;.73,-1.02,;1.64,.23,;.73,1.47,;1.13,2.96,;2.62,3.36,;3.02,4.85,;1.93,5.93,;.44,5.54,;.04,4.05,;-.73,1,;-2.07,1.77,;-3.4,1,;-3.4,-.54,;-2.07,-1.31,;-2.07,-2.85,;-.73,-3.62,;-.73,-5.16,;-2.07,-5.93,;-3.4,-5.16,;-4.73,-5.93,;-3.4,-3.62,;-.73,-.54,;-4.73,1.77,;-6.07,1,;-4.73,3.31,;2.07,-4.87,;3.4,-5.64,)|
Show InChI InChI=1S/C26H25ClN4O2/c1-16-7-9-17(10-8-16)14-31-15-21(18-5-3-2-4-6-18)23-24(31)22(29-25(30-23)26(32)33)19-11-20(27)13-28-12-19/h2-6,11-13,15-17H,7-10,14H2,1H3,(H,32,33)/t16-,17-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 72n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326304
PNG
(4-{[(1R)-1- cyclobutylethyl] amino}-5-[3-fluoro-4-...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(c(F)c3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H26F4N4O2/c1-15-5-3-8-19(11-15)23-13-22-24(36(23)14-17-9-10-20(21(29)12-17)28(30,31)32)25(35-26(34-22)27(37)38)33-16(2)18-6-4-7-18/h3,5,8-13,16,18H,4,6-7,14H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 87n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326319
PNG
(4-(5-chloropyridin-3-yl)-7- methyl-5-[(trans-4- me...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(C)c3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)CC1 |r,wU:4.4,wD:1.0,(6.07,-4.33,;4.73,-3.56,;4.73,-2.02,;3.4,-1.25,;2.07,-2.02,;.73,-1.25,;.73,.29,;1.64,1.54,;.73,2.79,;1.5,4.12,;-.73,2.31,;-2.07,3.08,;-3.4,2.31,;-3.4,.77,;-2.07,,;-2.07,-1.54,;-.73,-2.31,;-.73,-3.85,;-2.07,-4.62,;-3.4,-3.85,;-4.73,-4.62,;-3.4,-2.31,;-.73,.77,;-4.73,3.08,;-6.07,2.31,;-4.73,4.62,;2.07,-3.56,;3.4,-4.33,)|
Show InChI InChI=1S/C21H23ClN4O2/c1-12-3-5-14(6-4-12)11-26-10-13(2)17-19(26)18(25-20(24-17)21(27)28)15-7-16(22)9-23-8-15/h7-10,12,14H,3-6,11H2,1-2H3,(H,27,28)/t12-,14-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 88n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326316
PNG
(5-{4-(5-chloropyridin-3- yl)-5-[(trans-4- methylcy...)
Show SMILES C[C@H]1CC[C@H](Cn2ccc3nc(nc(-c4cncc(Cl)c4)c23)-c2n[nH]c(=O)o2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.23,;5.25,-4.46,;5.25,-2.92,;3.92,-2.15,;2.58,-2.92,;1.25,-2.15,;1.25,-.61,;2.16,.64,;1.25,1.88,;-.21,1.41,;-1.55,2.18,;-2.88,1.41,;-2.88,-.13,;-1.55,-.9,;-1.55,-2.44,;-.21,-3.21,;-.21,-4.75,;-1.55,-5.52,;-2.88,-4.75,;-4.22,-5.52,;-2.88,-3.21,;-.21,-.13,;-4.22,2.18,;-5.68,1.7,;-6.59,2.95,;-5.68,4.19,;-6.45,5.52,;-4.22,3.72,;2.58,-4.46,;3.92,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 95n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326292
PNG
(6-(1-benzofuran-5-yl)- 4-{[(1R)-1- cyclobutylethyl...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3ccc4occc4c3)n(Cc3ccc(cc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C29H25F3N4O3/c1-16(18-3-2-4-18)33-26-25-22(34-27(35-26)28(37)38)14-23(19-7-10-24-20(13-19)11-12-39-24)36(25)15-17-5-8-21(9-6-17)29(30,31)32/h5-14,16,18H,2-4,15H2,1H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 105n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326318
PNG
(3-{4-(3-chlorophenyl)-7- methyl-5-[(trans-4- methy...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(C)c3nc(nc(-c4cccc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.23,;5.25,-4.46,;5.25,-2.92,;3.92,-2.15,;2.58,-2.92,;1.25,-2.15,;1.25,-.61,;2.16,.64,;1.25,1.88,;2.02,3.21,;-.21,1.41,;-1.55,2.18,;-2.88,1.41,;-2.88,-.13,;-1.55,-.9,;-1.55,-2.44,;-.21,-3.21,;-.21,-4.75,;-1.55,-5.52,;-2.88,-4.75,;-4.22,-5.52,;-2.88,-3.21,;-.21,-.13,;-4.22,2.18,;-5.68,1.7,;-6.59,2.95,;-5.68,4.19,;-6.45,5.52,;-4.22,3.72,;2.58,-4.46,;3.92,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 107n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326311
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 5-(3-fluoro-4-...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(C)c(F)c3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H29FN4O2/c1-16-6-4-9-21(12-16)24-14-23-25(33(24)15-19-11-10-17(2)22(29)13-19)26(32-27(31-23)28(34)35)30-18(3)20-7-5-8-20/h4,6,9-14,18,20H,5,7-8,15H2,1-3H3,(H,34,35)(H,30,31,32)/t18-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 124n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326310
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 5-(3,4-difluor...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(F)c(F)c3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C27H26F2N4O2/c1-15-5-3-8-19(11-15)23-13-22-24(33(23)14-17-9-10-20(28)21(29)12-17)25(32-26(31-22)27(34)35)30-16(2)18-6-4-7-18/h3,5,8-13,16,18H,4,6-7,14H2,1-2H3,(H,34,35)(H,30,31,32)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 126n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326290
PNG
((R)-4-((1- cyclobutylethyl)amino)- 7-methyl-6-(m-t...)
Show SMILES C[C@@H](Nc1nc(nc2c(C)c(-c3cccc(C)c3)n(Cc3ccc(cc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C29H29F3N4O2/c1-16-6-4-9-21(14-16)24-17(2)23-25(36(24)15-19-10-12-22(13-11-19)29(30,31)32)26(35-27(34-23)28(37)38)33-18(3)20-7-5-8-20/h4,6,9-14,18,20H,5,7-8,15H2,1-3H3,(H,37,38)(H,33,34,35)/t18-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 130n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326313
PNG
(3-{4-(3-chlorophenyl)-5- [(trans-4- methylcyclohex...)
Show SMILES C[C@H]1CC[C@H](Cn2ccc3nc(nc(-c4cccc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1 |r,wU:4.4,wD:1.0,(6.59,-5.23,;5.25,-4.46,;5.25,-2.92,;3.92,-2.15,;2.58,-2.92,;1.25,-2.15,;1.25,-.61,;2.16,.64,;1.25,1.88,;-.21,1.41,;-1.55,2.18,;-2.88,1.41,;-2.88,-.13,;-1.55,-.9,;-1.55,-2.44,;-.21,-3.21,;-.21,-4.75,;-1.55,-5.52,;-2.88,-4.75,;-4.22,-5.52,;-2.88,-3.21,;-.21,-.13,;-4.22,2.18,;-5.68,1.7,;-6.59,2.95,;-5.68,4.19,;-6.45,5.52,;-4.22,3.72,;2.58,-4.46,;3.92,-5.23,)|
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 132n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326289
PNG
((R)-4-((1- cyclobutylethyl) amino)- 6-(m-tolyl)-5-...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(cc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H27F3N4O2/c1-16-5-3-8-20(13-16)23-14-22-24(35(23)15-18-9-11-21(12-10-18)28(29,30)31)25(34-26(33-22)27(36)37)32-17(2)19-6-4-7-19/h3,5,8-14,17,19H,4,6-7,15H2,1-2H3,(H,36,37)(H,32,33,34)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 140n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326308
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 6-(3-methylphe...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(nc3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C27H26F3N5O2/c1-15-5-3-8-19(11-15)21-12-20-23(35(21)14-17-9-10-22(31-13-17)27(28,29)30)24(34-25(33-20)26(36)37)32-16(2)18-6-4-7-18/h3,5,8-13,16,18H,4,6-7,14H2,1-2H3,(H,36,37)(H,32,33,34)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 178n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326317
PNG
(4-(3-chlorophenyl)-7- methyl-5-[(trans-4- methylcy...)
Show SMILES C[C@H]1CC[C@H](Cn2cc(C)c3nc(nc(-c4cccc(Cl)c4)c23)C(O)=O)CC1 |r,wU:4.4,wD:1.0,(6.07,-4.33,;4.73,-3.56,;4.73,-2.02,;3.4,-1.25,;2.07,-2.02,;.73,-1.25,;.73,.29,;1.64,1.54,;.73,2.79,;1.5,4.12,;-.73,2.31,;-2.07,3.08,;-3.4,2.31,;-3.4,.77,;-2.07,,;-2.07,-1.54,;-.73,-2.31,;-.73,-3.85,;-2.07,-4.62,;-3.4,-3.85,;-4.73,-4.62,;-3.4,-2.31,;-.73,.77,;-4.73,3.08,;-6.07,2.31,;-4.73,4.62,;2.07,-3.56,;3.4,-4.33,)|
Show InChI InChI=1S/C22H24ClN3O2/c1-13-6-8-15(9-7-13)12-26-11-14(2)18-20(26)19(25-21(24-18)22(27)28)16-4-3-5-17(23)10-16/h3-5,10-11,13,15H,6-9,12H2,1-2H3,(H,27,28)/t13-,15-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 226n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326314
PNG
(4-(5-chloropyridin-3-yl)-5- [(trans-4- methylcyclo...)
Show SMILES C[C@H]1CC[C@H](Cn2ccc3nc(nc(-c4cncc(Cl)c4)c23)C(O)=O)CC1 |r,wU:4.4,wD:1.0,(6.07,-4.33,;4.73,-3.56,;4.73,-2.02,;3.4,-1.25,;2.07,-2.02,;.73,-1.25,;.73,.29,;1.64,1.54,;.73,2.79,;-.73,2.31,;-2.07,3.08,;-3.4,2.31,;-3.4,.77,;-2.07,,;-2.07,-1.54,;-.73,-2.31,;-.73,-3.85,;-2.07,-4.62,;-3.4,-3.85,;-4.73,-4.62,;-3.4,-2.31,;-.73,.77,;-4.73,3.08,;-6.07,2.31,;-4.73,4.62,;2.07,-3.56,;3.4,-4.33,)|
Show InChI InChI=1S/C20H21ClN4O2/c1-12-2-4-13(5-3-12)11-25-7-6-16-18(25)17(24-19(23-16)20(26)27)14-8-15(21)10-22-9-14/h6-10,12-13H,2-5,11H2,1H3,(H,26,27)/t12-,13-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 247n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326301
PNG
(4-{[(1R)-1- cyclobutylethyl] amino}-5-[3-fluoro-4-...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(OC(F)(F)F)c(F)c3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H26F4N4O3/c1-15-5-3-8-19(11-15)22-13-21-24(25(35-26(34-21)27(37)38)33-16(2)18-6-4-7-18)36(22)14-17-9-10-23(20(29)12-17)39-28(30,31)32/h3,5,8-13,16,18H,4,6-7,14H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 267n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326312
PNG
(4-(3-chlorophenyl)-5- [(trans-4- methylcyclohexyl)...)
Show SMILES C[C@H]1CC[C@H](Cn2ccc3nc(nc(-c4cccc(Cl)c4)c23)C(O)=O)CC1 |r,wU:4.4,wD:1.0,(6.07,-4.33,;4.73,-3.56,;4.73,-2.02,;3.4,-1.25,;2.07,-2.02,;.73,-1.25,;.73,.29,;1.64,1.54,;.73,2.79,;-.73,2.31,;-2.07,3.08,;-3.4,2.31,;-3.4,.77,;-2.07,,;-2.07,-1.54,;-.73,-2.31,;-.73,-3.85,;-2.07,-4.62,;-3.4,-3.85,;-4.73,-4.62,;-3.4,-2.31,;-.73,.77,;-4.73,3.08,;-6.07,2.31,;-4.73,4.62,;2.07,-3.56,;3.4,-4.33,)|
Show InChI InChI=1S/C21H22ClN3O2/c1-13-5-7-14(8-6-13)12-25-10-9-17-19(25)18(24-20(23-17)21(26)27)15-3-2-4-16(22)11-15/h2-4,9-11,13-14H,5-8,12H2,1H3,(H,26,27)/t13-,14-
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 294n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326300
PNG
(4-{[(1R)-1- cyclobutylethyl] amino}-6-(3- methylph...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(OC(F)(F)F)cc3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H27F3N4O3/c1-16-5-3-8-20(13-16)23-14-22-24(35(23)15-18-9-11-21(12-10-18)38-28(29,30)31)25(34-26(33-22)27(36)37)32-17(2)19-6-4-7-19/h3,5,8-14,17,19H,4,6-7,15H2,1-2H3,(H,36,37)(H,32,33,34)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 348n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326288
PNG
((R)-4-((1- cyclobutylethyl)amino)- 7-(2-fluoro-5- ...)
Show SMILES C[C@@H](Nc1nc(nc2c(cn(Cc3ccc(cc3)C(F)(F)F)c12)-c1cc(C)ccc1F)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H26F4N4O2/c1-15-6-11-22(29)20(12-15)21-14-36(13-17-7-9-19(10-8-17)28(30,31)32)24-23(21)34-26(27(37)38)35-25(24)33-16(2)18-4-3-5-18/h6-12,14,16,18H,3-5,13H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 353n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326307
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 5-[4- (difluor...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(cc3)C(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H28F2N4O2/c1-16-5-3-8-21(13-16)23-14-22-24(34(23)15-18-9-11-20(12-10-18)25(29)30)26(33-27(32-22)28(35)36)31-17(2)19-6-4-7-19/h3,5,8-14,17,19,25H,4,6-7,15H2,1-2H3,(H,35,36)(H,31,32,33)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 530n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326294
PNG
(7-(2-chloro-5- methylphenyl)-4-{[(1R)- 1- cyclobut...)
Show SMILES C[C@@H](Nc1nc(nc2c(cn(Cc3ccc(cc3)C(F)(F)F)c12)-c1cc(C)ccc1Cl)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H26ClF3N4O2/c1-15-6-11-22(29)20(12-15)21-14-36(13-17-7-9-19(10-8-17)28(30,31)32)24-23(21)34-26(27(37)38)35-25(24)33-16(2)18-4-3-5-18/h6-12,14,16,18H,3-5,13H2,1-2H3,(H,37,38)(H,33,34,35)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 712n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326299
PNG
(4-{[(1R)-1- cyclobutylethyl] amino}-6-(3- methylph...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(cn3)C(F)(F)F)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C27H26F3N5O2/c1-15-5-3-8-18(11-15)22-12-21-23(35(22)14-20-10-9-19(13-31-20)27(28,29)30)24(34-25(33-21)26(36)37)32-16(2)17-6-4-7-17/h3,5,8-13,16-17H,4,6-7,14H2,1-2H3,(H,36,37)(H,32,33,34)/t16-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 844n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326303
PNG
(4-{[(1R)-1- cyclobutylethyl] amino}-5-[4- (difluor...)
Show SMILES C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(OC(F)F)cc3)c12)C(O)=O)C1CCC1 |r|
Show InChI InChI=1S/C28H28F2N4O3/c1-16-5-3-8-20(13-16)23-14-22-24(34(23)15-18-9-11-21(12-10-18)37-28(29)30)25(33-26(32-22)27(35)36)31-17(2)19-6-4-7-19/h3,5,8-14,17,19,28H,4,6-7,15H2,1-2H3,(H,35,36)(H,31,32,33)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.78E+3n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326302
PNG
(4-{[(1R)-1- cyclobutylethyl]amino}- 5-[2-methoxy-4...)
Show SMILES COc1cc(OC(F)(F)F)ccc1Cn1c(cc2nc(nc(N[C@H](C)C3CCC3)c12)C(O)=O)-c1cccc(C)c1 |r|
Show InChI InChI=1S/C29H29F3N4O4/c1-16-6-4-9-19(12-16)23-14-22-25(26(35-27(34-22)28(37)38)33-17(2)18-7-5-8-18)36(23)15-20-10-11-21(13-24(20)39-3)40-29(30,31)32/h4,6,9-14,17-18H,5,7-8,15H2,1-3H3,(H,37,38)(H,33,34,35)/t17-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 4.37E+3n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
E3 ubiquitin-protein ligase Mdm2 [17-125]


(Homo sapiens (Human))		BDBM326305
PNG
(4-{[(1R)-1- cyclobutylethyl] amino}-5-(4- methoxyb...)
Show SMILES COc1ccc(Cn2c(cc3nc(nc(N[C@H](C)C4CCC4)c23)C(O)=O)-c2cccc(C)c2)cc1 |r|
Show InChI InChI=1S/C28H30N4O3/c1-17-6-4-9-21(14-17)24-15-23-25(32(24)16-19-10-12-22(35-3)13-11-19)26(31-27(30-23)28(33)34)29-18(2)20-7-5-8-20/h4,6,9-15,18,20H,5,7-8,16H2,1-3H3,(H,33,34)(H,29,30,31)/t18-/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 6.19E+3n/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM...

US Patent US9637493 (2017)


BindingDB Entry DOI: 10.7270/Q28917Z1
More data for this
Ligand-Target Pair
* indicates data uncertainty>20%